BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60-89. [PMID: 24713006 DOI: 10.1111/jvh.12249] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 17.4] [Reference Citation Analysis]
Number Citing Articles
1 Wedemeyer H. Towards interferon-free treatment for all HCV genotypes. Lancet 2015;385:2443-5. [PMID: 25837828 DOI: 10.1016/S0140-6736(15)60605-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
2 Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Mauss S, Rossol S. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial. J Viral Hepat 2016;23:105-15. [PMID: 26411532 DOI: 10.1111/jvh.12471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
3 Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ 2018;21:1-10. [PMID: 28881157 DOI: 10.1080/13696998.2017.1369983] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
4 Altınbas S, Holmes JA, Altınbas A. Hepatitis C Virus Infection in Pregnancy: An Update. Gastroenterol Nurs 2020;43:12-21. [PMID: 31990870 DOI: 10.1097/SGA.0000000000000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
5 Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017;9:17-25. [PMID: 28553150 DOI: 10.2147/HMER.S113681] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 13.2] [Reference Citation Analysis]
6 Innes H, Goldberg D, Dillon J, Hutchinson SJ. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut 2015;64:1800-9. [PMID: 25378522 DOI: 10.1136/gutjnl-2014-308166] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
7 Gardini I, Bartoli M, Conforti M, Mennini FS, Marcellusi A. Estimation of the number of HCV-positive patients in Italy. PLoS One 2019;14:e0223668. [PMID: 31671120 DOI: 10.1371/journal.pone.0223668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Schaerer V, Haubitz S, Kovari H, Ledergerber B, Ambrosioni J, Cavassini M, Stoeckle M, Schmid P, Decosterd L, Aouri M, Böni J, Günthard HF, Furrer H, Metzner KJ, Fehr J, Rauch A; Swiss HIV Cohort Study. Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Med 2015;16:599-607. [PMID: 26135140 DOI: 10.1111/hiv.12269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
9 Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, Salupere R, Assiri AM, Goldis A, Abaalkhail F, Abbas Z, Abdou A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alavian SM, Alashgar HI, Alawadhi S, Al-dabal L, Aldins P, Alfaleh FZ, Alghamdi AS, Al-hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Alzaabi M, Andrea N, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Blach S, Chaudhry A, Choi MS, Diab T, Djauzi S, El Hassan ES, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Gheorghe L, Gottfredsson M, Gregorcic S, Gunter J, Hajarizadeh B, Hamid S, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jeruma A, Jonasson JG, Karlsdottir B, Kim DY, Kim YS, Koutoubi Z, Liakina V, Lim YS, Löve A, Maimets M, Malekzadeh R, Matičič M, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Nugrahini N, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-shearer D, Razavi-shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Sharara AI, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tanaka J, Tarifi H, Tayyab G, Tolmane I, Ud din M, Umar M, Valantinas J, Videčnik-zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, Schmelzer JD. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat 2015;22:21-41. [DOI: 10.1111/jvh.12476] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
10 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
11 Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34-59. [PMID: 24713005 DOI: 10.1111/jvh.12248] [Cited by in Crossref: 251] [Cited by in F6Publishing: 240] [Article Influence: 31.4] [Reference Citation Analysis]
12 Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology & Hepatology 2016;1:317-27. [DOI: 10.1016/s2468-1253(16)30075-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
13 Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22. [PMID: 25347030 DOI: 10.1517/14656566.2014.972364] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
14 Clarke JL, Paruch L, Dobrica MO, Caras I, Tucureanu C, Onu A, Ciulean S, Stavaru C, Eerde A, Wang Y, Steen H, Haugslien S, Petrareanu C, Lazar C, Popescu CI, Bock R, Dubuisson J, Branza-Nichita N. Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination. Plant Biotechnol J 2017;15:1611-21. [PMID: 28419665 DOI: 10.1111/pbi.12743] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
15 Chung YS, Choi JY, Han MG, Park KR, Park SJ, Lee H, Jee Y, Kang C. A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea. J Clin Virol 2018;106:53-7. [PMID: 30075460 DOI: 10.1016/j.jcv.2018.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Donnison T, Chinnakannan S, Cicconi P, Barnes E. Hepatitis C vaccines: how close are we to the promised land? In: Foster GR, Reddy KR, editors. Clinical Dilemmas in Viral Liver Disease. Wiley; 2020. pp. 208-15. [DOI: 10.1002/9781119533481.ch36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Béguelin C, Suter A, Bernasconi E, Fehr J, Kovari H, Bucher HC, Stoeckle M, Cavassini M, Rougemont M, Schmid P, Wandeler G, Rauch A; Swiss HIV Cohort Study. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver Int 2018;38:424-31. [PMID: 28741901 DOI: 10.1111/liv.13528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
18 Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718-735. [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011] [Cited by in Crossref: 211] [Cited by in F6Publishing: 190] [Article Influence: 52.8] [Reference Citation Analysis]
19 Silvestri C, Bartolacci S, Pepe P, Monnini M, Voller F, Cipriani F, Stasi C. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data. World J Gastroenterol 2016; 22(44): 9829-9835 [PMID: 27956807 DOI: 10.3748/wjg.v22.i44.9829] [Reference Citation Analysis]
20 Machado SM, Almeida C Neto, Pinho JRR, Malta FM, Capuani L, Campos AF, Abreu FRM, Nastri ACSS, Santana RAF, Sabino EC, Mendes-Correa MC. Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up. Rev Saude Publica 2017;51:40. [PMID: 28489184 DOI: 10.1590/S1518-8787.2017051006468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
21 Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 2017;17:215-22. [PMID: 28029529 DOI: 10.1016/S1473-3099(16)30408-X] [Cited by in Crossref: 74] [Cited by in F6Publishing: 23] [Article Influence: 12.3] [Reference Citation Analysis]
22 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
23 Martinello M, Bajis S, Dore GJ. Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation. Gastroenterol Clin North Am 2020;49:253-77. [PMID: 32389362 DOI: 10.1016/j.gtc.2020.01.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ow T, Ralton L, Tse E. Saving costs through a coordinated care model for patients with hepatocellular cancer: Cost saving with HCC care coordination. Intern Med J 2017;47:1005-11. [DOI: 10.1111/imj.13465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
25 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
26 Razavi H, Bruggmann P, Wedemeyer H, Dore G. Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat 2014;21:e169-70. [DOI: 10.1111/jvh.12339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Mariño Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother 2015;16:1929-43. [PMID: 26219918 DOI: 10.1517/14656566.2015.1070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Stahmeyer JT, Rossol S, Krauth C. Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. J Comp Eff Res 2015;4:267-77. [PMID: 25960028 DOI: 10.2217/cer.15.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
29 Ali S, Ali M, Paudyal V, Rasheed F, Ullah S, Haque S, Ur-Rehman T. A Randomized Controlled Trial to Assess the  Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients. Patient Prefer Adherence 2019;13:2089-100. [PMID: 31997877 DOI: 10.2147/PPA.S224937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79. [PMID: 29433454 DOI: 10.1186/s12879-018-2988-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
31 Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. [PMID: 28694740 DOI: 10.4103/jcar.JCar_9_16] [Cited by in Crossref: 313] [Cited by in F6Publishing: 221] [Article Influence: 62.6] [Reference Citation Analysis]
32 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
33 Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ, Goldberg DJ, Martin TCS, Ramsay M, Hickman M; STOP-HCV Consortium. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol 2016;65:17-25. [PMID: 26867489 DOI: 10.1016/j.jhep.2016.02.007] [Cited by in Crossref: 135] [Cited by in F6Publishing: 124] [Article Influence: 22.5] [Reference Citation Analysis]
34 Solbach P, Wedemeyer H. The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Viszeralmedizin 2015;31:290-6. [PMID: 26557839 DOI: 10.1159/000433594] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
35 Gane E. Hepatitis C beware—the end is nigh. The Lancet 2014;384:1557-60. [DOI: 10.1016/s0140-6736(14)61225-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 2.1] [Reference Citation Analysis]
36 Younossi ZM, LaLuna LL, Santoro JJ, Mendes F, Araya V, Ravendhran N, Pedicone L, Lio I, Nader F, Hunt S, Racila A, Stepanova M. Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. BMC Gastroenterol 2016;16:45. [PMID: 27044402 DOI: 10.1186/s12876-016-0438-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
37 Sandmann L, Manns MP, Maasoumy B. Utility of viral kinetics in HCV therapy - It is not over until it is over? Liver Int 2019;39:815-7. [PMID: 31020775 DOI: 10.1111/liv.14047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One 2015;10:e0126920. [PMID: 25961575 DOI: 10.1371/journal.pone.0126920] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
39 Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol 2017;11:85-93. [PMID: 27500437 DOI: 10.1080/17474124.2016.1222271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
40 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 394] [Cited by in F6Publishing: 334] [Article Influence: 65.7] [Reference Citation Analysis]
41 van der Meer AJ. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease? Expert Review of Gastroenterology & Hepatology 2015;9:559-66. [DOI: 10.1586/17474124.2015.1001366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
42 Olmos-Martínez JM, Hernández JL, Fábrega E, Olmos JM, Crespo J, González-Macías J. Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection. Arch Osteoporos 2020;15:72. [PMID: 32399944 DOI: 10.1007/s11657-020-00752-1] [Reference Citation Analysis]
43 Gounder PP, Koch A, Provo G, Lovlie A, Ederth JL, Axelsson M, Archibald CP, Hanley B, Mullen A, Matheson M, Allison D, Trykker H, Hennessy TW, Kuusi M, Chulanov V, McMahon BJ. Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. Euro Surveill 2018;23. [PMID: 30301489 DOI: 10.2807/1560-7917.ES.2018.23.40.1700408] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach. Journal of Hepatology 2015;62:469-76. [DOI: 10.1016/j.jhep.2014.10.008] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 11.3] [Reference Citation Analysis]
45 Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat 2015;22 Suppl 1:1-5. [PMID: 25560838 DOI: 10.1111/jvh.12371] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
46 Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis 2016;16:735-45. [PMID: 27301929 DOI: 10.1016/S1473-3099(16)00120-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
47 Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46 Suppl 5:S158-S164. [PMID: 25453870 DOI: 10.1016/j.dld.2014.09.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
48 Bellanti F, Lauletta G, Villani R, Lipsi MR, Natalicchio MI, Sansonno D, Vendemiale G, Serviddio G. Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins. Medicine (Baltimore) 2015;94:e1409. [PMID: 26334898 DOI: 10.1097/MD.0000000000001409] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014;29 Suppl 1:1-9. [PMID: 25055928 DOI: 10.1111/jgh.12677] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
50 Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, Gheorghe L, El Hassan ES, Abaalkhail F, Abbas Z. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat. 2015;22 Suppl 4:4-20. [PMID: 26513445 DOI: 10.1111/jvh.12475] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 10.5] [Reference Citation Analysis]
51 Vine LJ, Sieberhagen C, Cramp ME. Diagnosis and management of hepatitis C. Br J Hosp Med (Lond) 2015;76:625-30. [PMID: 26551491 DOI: 10.12968/hmed.2015.76.11.625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
52 Hardtke S, Wedemeyer H. Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte. Gastroenterologe 2015;10:305-9. [DOI: 10.1007/s11377-015-0995-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Boesecke C, Rockstroh JK. How will we manage acute HCV in men having sex with men in the era of all oral therapy? J Viral Hepat 2015;22:2-7. [PMID: 25333810 DOI: 10.1111/jvh.12348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
54 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect 2017;145:2873-85. [PMID: 28891457 DOI: 10.1017/S0950268817001947] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
56 Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015;22:399-408. [PMID: 25288193 DOI: 10.1111/jvh.12338] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 9.6] [Reference Citation Analysis]
57 Pinto FP, Ferreira OC Jr, Olmedo DB, Precioso PM, Barquette FR, Castilho MC, Silva SG, Pôrto LC. Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study. Ann Hepatol 2015;14:815-25. [PMID: 26436353 DOI: 10.5604/16652681.1171756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Minaei AA, Kowdley KV. ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother 2015;16:929-37. [PMID: 25800085 DOI: 10.1517/14656566.2015.1024653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
59 Bartenschlager R, Cornberg M, Pietschmann T. [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E]. Internist (Berl) 2017;58:666-74. [PMID: 28631044 DOI: 10.1007/s00108-017-0262-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open 2019;9:e029538. [PMID: 31551376 DOI: 10.1136/bmjopen-2019-029538] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
61 McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? J Hepatol 2015;62:262-8. [PMID: 25195556 DOI: 10.1016/j.jhep.2014.08.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
62 Hardtke S, Wiebner B, Manns MP. [From the national competence network for viral hepatitis (HepNet) emerged the German Liver Foundation (Deutsche Leberstiftung)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016;59:482-8. [PMID: 26942931 DOI: 10.1007/s00103-016-2319-6] [Reference Citation Analysis]
63 Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, Elfayomy M, Abdel-Ghafar TS, Abdelkareem M, Sabry A, Fekry M, Shebl N, Rewisha E, Waked I. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis 2018;75:109-14. [PMID: 30077791 DOI: 10.1016/j.ijid.2018.07.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
64 Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm - volume 2. J Viral Hepat. 2015;22 Suppl 1:26-45. [PMID: 25560840 DOI: 10.1111/jvh.12351] [Cited by in Crossref: 93] [Cited by in F6Publishing: 82] [Article Influence: 13.3] [Reference Citation Analysis]
65 Carvalho-Louro DM, Soares EB, Trevizoli JE, Marra TMG, da Cunha ALR, Rodrigues MP, Carvalho-Furtado ACL, Dos Santos BTA, de Assis da Rocha Neves F. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis 2020;20:114. [PMID: 32041537 DOI: 10.1186/s12879-020-4809-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
66 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
67 Ullah N, Kakakhel MA, Bai Y, Xi L, Khan I, Kalra BS, Kumar T, Ahmad H, Shah M, Guanlan L, Zhang C. Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Braz J Biol 2021;83:e244977. [PMID: 34287506 DOI: 10.1590/1519-6984.244977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Bajis S, Applegate TL, Grebely J, Matthews GV, Dore GJ. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis 2020;222:S758-72. [PMID: 33245354 DOI: 10.1093/infdis/jiaa366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Houri I, Horowitz N, Katchman H, Weksler Y, Miller O, Deutsch L, Shibolet O. Emergency department targeted screening for hepatitis C does not improve linkage to care. World J Gastroenterol 2020; 26(32): 4878-4888 [PMID: 32921964 DOI: 10.3748/wjg.v26.i32.4878] [Reference Citation Analysis]
70 Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, Wolffram I, Petroff D, Aidelsburger P, Grünbauer A, Neumann A. Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. Scand J Gastroenterol 2018;53:76-82. [PMID: 29065740 DOI: 10.1080/00365521.2017.1390599] [Reference Citation Analysis]
71 Rosińska M, Parda N, Kołakowska A, Godzik P, Zakrzewska K, Madaliński K, Zieliński A, Boguradzka A, Gierczyński R, Stępień M. Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016. PLoS One 2017;12:e0185055. [PMID: 28931062 DOI: 10.1371/journal.pone.0185055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
72 Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0141715. [PMID: 26558905 DOI: 10.1371/journal.pone.0141715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
73 Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat. 2015;22 Suppl 1:6-25. [PMID: 25560839 DOI: 10.1111/jvh.12350] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 11.6] [Reference Citation Analysis]
74 Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology 2015;62:31-9. [PMID: 25581111 DOI: 10.1002/hep.27691] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
75 Kramer J, Wolffram I, Früh U, Bätz O, Berg T, Wiegand J. Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany. J Viral Hepat 2019;26:1493-5. [PMID: 31386783 DOI: 10.1111/jvh.13188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Hashim A, O'Sullivan M, Williams H, Verma S. Developing a community HCV service: project ITTREAT (integrated community-based test - stage - TREAT) service for people who inject drugs. Prim Health Care Res Dev 2018;19:110-20. [PMID: 29199921 DOI: 10.1017/S1463423617000731] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Lüllau A, Petroff D, Bätz O, Kramer J, Jedrysiak K, Tenckhoff H, Berg T, Wolffram I, Wiegand J. Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. Eur J Gastroenterol Hepatol 2018;30:280-3. [PMID: 29324587 DOI: 10.1097/MEG.0000000000001052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87-S99. [PMID: 25920094 DOI: 10.1016/j.jhep.2015.02.006] [Cited by in Crossref: 217] [Cited by in F6Publishing: 205] [Article Influence: 36.2] [Reference Citation Analysis]
79 Waheed Y. Hepatitis C eradication: A long way to go. World J Gastroenterol 2015;21:12510-2. [PMID: 26604658 DOI: 10.3748/wjg.v21.i43.12510] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
80 Daw MA, El-Bouzedi AA, Ahmed MO, Dau AA, Agnan MM, Drah AM. Geographic integration of hepatitis C virus: A global threat. World J Virol 2016; 5(4): 170-182 [PMID: 27878104 DOI: 10.5501/wjv.v5.i4.170] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
81 Tacke F, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. Liver Transpl. 2016;22:1136-1142. [PMID: 27082951 DOI: 10.1002/lt.24461] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 10.2] [Reference Citation Analysis]
82 Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. BMC Infect Dis 2016;16:565. [PMID: 27733137 DOI: 10.1186/s12879-016-1883-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
83 Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 2015;28:576-82. [PMID: 26524330 DOI: 10.1097/QCO.0000000000000216] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 10.2] [Reference Citation Analysis]
84 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
85 Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40:522-529. [PMID: 31815353 DOI: 10.1111/liv.14324] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 17.0] [Reference Citation Analysis]
86 Alboraie M, Schütte K, Khairy M, Elsharkawy M, Asem N, Elghamry F, Shalaby H, Esmat G, Malfertheiner P. Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C. Saudi Med J 2017;38:1137-42. [PMID: 29114703 DOI: 10.15537/smj.2017.11.21220] [Reference Citation Analysis]
87 Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J 2018;6:213-24. [PMID: 29511551 DOI: 10.1177/2050640617716607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
88 Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G, Gilmore I, Hickman M, Hudson M, Kelly D, Langford A, Lombard M, Longworth L, Martin N, Moriarty K, Newsome P, O'Grady J, Pryke R, Rutter H, Ryder S, Sheron N, Smith T. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384:1953-1997. [PMID: 25433429 DOI: 10.1016/s0140-6736(14)61838-9] [Cited by in Crossref: 322] [Cited by in F6Publishing: 151] [Article Influence: 46.0] [Reference Citation Analysis]
89 Kao J, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng C, Roberts SK, Lee Y, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int 2016;36:954-62. [DOI: 10.1111/liv.13049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
90 Wróblewska A, Bernat A, Woziwodzka A, Markiewicz J, Romanowski T, Bielawski KP, Smiatacz T, Sikorska K. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. Clin Exp Med 2017;17:225-32. [PMID: 27125837 DOI: 10.1007/s10238-016-0423-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
91 Zachoval R, Jung MC. [Chronic Hepatitis C - Therapeutic Options in 2016]. MMW Fortschr Med 2016;158 Suppl 1:54-7. [PMID: 27259905 DOI: 10.1007/s15006-016-8329-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
92 Neto MF, Butzler MA, Reed JL, Rui X, Fisher MJ, Kelso DM, McFall SM. Immiscible phase filter extraction and equivalent amplification of genotypes 1-6 of hepatitis C RNA: The building blocks for point-of-care diagnosis. J Virol Methods 2017;248:107-15. [PMID: 28673855 DOI: 10.1016/j.jviromet.2017.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
93 Adinolfi LE, Guerrera B. All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol 2015; 7(22): 2363-2368 [PMID: 26464751 DOI: 10.4254/wjh.v7.i22.2363] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
94 Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden - volume 3 (editorial). J Viral Hepat. 2015;22 Suppl 4:1-3. [PMID: 26513444 DOI: 10.1111/jvh.12473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
95 Şahin AR, Erdoğan A, Gisi K, İspiroğlu M, Ateş S, Okyay RA, Nazik S, Kantarçeken B. Can family physicians have a role in eradication of hepatitis c infection? Turk J Gastroenterol 2020;31:393-9. [PMID: 32519959 DOI: 10.5152/tjg.2020.19913] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol 2019; 25(11): 1327-1340 [PMID: 30918426 DOI: 10.3748/wjg.v25.i11.1327] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
97 Sbarigia U, Wirth D, Van Nuys K, Huber C, Brookmeyer R, Stahmeyer J, Krauth C. Economic study of the value of expanding HCV treatment capacity in Germany. BMJ Open Gastroenterol 2017;4:e000130. [PMID: 28461903 DOI: 10.1136/bmjgast-2016-000130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
98 Cornberg M, Manns MP. The curing regimens of HCV: A SWOT analysis. Antivir Ther 2022;27:13596535211072672. [PMID: 35491553 DOI: 10.1177/13596535211072672] [Reference Citation Analysis]
99 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
100 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
101 Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect 2017;6:e95. [PMID: 29089588 DOI: 10.1038/emi.2017.77] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
102 Deltenre P. Studies on the epidemiology of hepatitis B and C virus infections are still needed. Journal of Hepatology 2015;62:1225-7. [DOI: 10.1016/j.jhep.2015.02.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
103 Ghasemi F, Rostami S, Meshkat Z. Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol 2015; 21(42): 11984-12002 [PMID: 26576087 DOI: 10.3748/wjg.v21.i42.11984] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
104 Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH. Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Gut Liver 2017;11:543-50. [PMID: 28506027 DOI: 10.5009/gnl16530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
105 Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis 2018;18:42. [PMID: 29338702 DOI: 10.1186/s12879-017-2908-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
106 Kuo M, Janjua NZ, Burchell AN, Buxton JA, Krajden M, Gilbert M. Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011. Am J Public Health 2015;105:1604-10. [PMID: 26066920 DOI: 10.2105/AJPH.2015.302591] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
107 Höner zu Siederdissen C, Maasoumy B, Deterding K, Port K, Sollik L, Mix C, Kirschner J, Cornberg J, Manns MP, Wedemeyer H, Cornberg M. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver Int 2015;35:1845-52. [DOI: 10.1111/liv.12774] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
108 Hickman M, Martin N, Vickerman P, Hutchinson S. Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat 2014;21:e167-8. [DOI: 10.1111/jvh.12340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Stvilia K, Vephkvadze N, Gamkrelidze A, Khonelidze I, Getia V, Tsereteli M, Gvinjilia L, Kuchuloria T. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. Public Health 2021;195:42-50. [PMID: 34051674 DOI: 10.1016/j.puhe.2021.03.017] [Reference Citation Analysis]
110 Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. J Gastroenterol Hepatol. 2017;32:466-472. [PMID: 27403912 DOI: 10.1111/jgh.13485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
111 Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology 2018;67:837-46. [PMID: 29059461 DOI: 10.1002/hep.29611] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 10.8] [Reference Citation Analysis]
112 Balasubramanian K, Patil VM. Quantum molecular modeling of hepatitis C virus inhibition through non-structural protein 5B polymerase receptor binding of C5-arylidene rhodanines. Comput Biol Chem 2018;73:147-58. [PMID: 29486389 DOI: 10.1016/j.compbiolchem.2018.01.008] [Reference Citation Analysis]
113 Masarone M, Caruso R, Aglitti A, Izzo C, De Matteis G, Attianese MR, Pagano AM, Persico M. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. Dig Liver Dis 2020;52:541-6. [PMID: 32234417 DOI: 10.1016/j.dld.2020.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
114 Dore GJ, Hatzakis A, Negro F, Waked I. Estimating HCV disease burden-volume 4 (editorial). J Viral Hepat 2017;24 Suppl 2:4-7. [PMID: 29105284 DOI: 10.1111/jvh.12763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Ingiliz P. Editorial to Martinello et al.'s HCV reinfection incidence among individuals treated for recent infection. J Viral Hepat 2017;24:357-8. [PMID: 28170123 DOI: 10.1111/jvh.12686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
116 Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-S57. [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027] [Cited by in Crossref: 1189] [Cited by in F6Publishing: 1085] [Article Influence: 148.6] [Reference Citation Analysis]
117 Örmeci N, Gülşen MT, Sezgin O, Aghayeva S, Demir M, Köksal I, Güner R, Erarslan E, Asiller ÖÖ, Balkan A, Yaraş S, Çalışkan Kartal A. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020;31:148-55. [PMID: 32141824 DOI: 10.5152/tjg.2020.19440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66:485-93. [PMID: 27780714 DOI: 10.1016/j.jhep.2016.10.017] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 24.7] [Reference Citation Analysis]
119 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
120 Falla AM, Veldhuijzen IK, Ahmad AA, Levi M, Richardus JH. Language support for linguistic minority chronic hepatitis B/C patients: an exploratory study of availability and clinicians' perceptions of language barriers in six European countries. BMC Health Serv Res 2017;17:150. [PMID: 28219385 DOI: 10.1186/s12913-017-2095-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
121 Schneider MD, Kronenberger B, Zeuzem S, Sarrazin C. [Treatment of hepatitis C]. Internist (Berl). 2015;56:391-405. [PMID: 25762008 DOI: 10.1007/s00108-015-3667-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
122 Wedemeyer H. [Treatment of hepatitis C: what is known?]. Internist (Berl) 2014;55:1419-26. [PMID: 25465278 DOI: 10.1007/s00108-014-3554-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
123 El-Ghitany EM, Farghaly AG. Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon 2019;5:e02249. [PMID: 31463388 DOI: 10.1016/j.heliyon.2019.e02249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
124 Wolffram I, Petroff D, Bätz O, Jedrysiak K, Kramer J, Tenckhoff H, Berg T, Wiegand J. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. Journal of Hepatology 2015;62:1256-64. [DOI: 10.1016/j.jhep.2015.01.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
125 Lee MY, Chen WC, Hsu WH, Chen SC, Lee JC. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism. Int J Mol Sci 2019;20:E4569. [PMID: 31540136 DOI: 10.3390/ijms20184569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Heidrich B, Steinmann E, Plumeier I, Kirschner J, Sollik L, Ziegert S, Engelmann M, Lehmann P, Manns MP, Pieper DH, Wedemeyer H. Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. Journal of Clinical Virology 2016;80:1-7. [DOI: 10.1016/j.jcv.2016.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
127 Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 2018;68:402-11. [PMID: 29080808 DOI: 10.1016/j.jhep.2017.10.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 18.0] [Reference Citation Analysis]
128 Maasoumy B, Vermehren J. Diagnostics in hepatitis C: The end of response-guided therapy? J Hepatol 2016;65:S67-81. [PMID: 27641989 DOI: 10.1016/j.jhep.2016.07.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
129 Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. J Hepatol. 2017;. [PMID: 29223371 DOI: 10.1016/j.jhep.2017.11.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
130 Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol 2015;50:233-44. [PMID: 25515032 DOI: 10.3109/00365521.2014.990505] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
131 Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat 2016;23 Suppl 1:1-12. [PMID: 26809941 DOI: 10.1111/jvh.12493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
132 Carlisle LA, Turk T, Metzner KJ, Mbunkah HA, Shah C, Böni J, Huber M, Braun DL, Fehr J, Salazar-Vizcaya L, Rauch A, Yerly S, Nguyen A, Cavassini M, Stoeckle M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD. HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. Viruses 2020;12:E1241. [PMID: 33142675 DOI: 10.3390/v12111241] [Reference Citation Analysis]
133 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
134 Olmedo DB, Precioso PM, Lugdero-Correia A, Silva GD, Santos AMGD, Pôrto LC. Exposure source prevalence is associated with gender in hepatitis C virus patients from Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 2017;112:632-9. [PMID: 28902289 DOI: 10.1590/0074-02760160553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]